Prof. Liljana Stevceva holds a medical degree from the University Kiril i Metodi, Skopje, Macedonia and a PhD from John Curtin School of Medical Research, Australian National University. Dr. Stevceva has over 10 years clinical practice prior to switching her career path to research. She is highly trained in both basic and clinical research by some of the top-ranking institutions in the USA such as National Cancer Institute, Harvard Medical School, Massachusetts General Hospital, National Institute of Allergy and Infectious Diseases and others.

Dr. Stevceva has 25 years of experience in vaccine development. In addition, her expertise includes CAR T cell therapy, cancer, immune-mediated diseases, autoimmune diseases, transplant, vaccines, and infectious diseases. CAR T cell therapies and Tumor Infiltrating Lymphocytes-TIL therapy for Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma, non-Hodgkin Lymphoma, Hodgkin Lymphoma, Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia, Multiple Myeloma, Glioblastoma and other. She had worked on pediatric clinical trials and clinical trials in adults.

LinkedIn: https://www.linkedin.com/in/liljana-stevceva-a286b05/

ResearchGate: https://www.researchgate.net/profile/Liljana-Stevceva/stats